<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054717</url>
  </required_header>
  <id_info>
    <org_study_id>1182.12</org_study_id>
    <nct_id>NCT00054717</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)</brief_title>
  <official_title>Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment
      regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response at Week 48</measure>
    <time_frame>At week 48</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Treatment Failure Through 48 Weeks of Treatment</measure>
    <time_frame>Week 48</time_frame>
    <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 2</measure>
    <time_frame>week 2</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 4</measure>
    <time_frame>week 4</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 8</measure>
    <time_frame>week 8</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 16</measure>
    <time_frame>week 16</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 56</measure>
    <time_frame>week 56</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 64</measure>
    <time_frame>week 64</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 88</measure>
    <time_frame>Week 88</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure Through 96 Weeks of Treatment</measure>
    <time_frame>Week 96</time_frame>
    <description>time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</measure>
    <time_frame>Week 48</time_frame>
    <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</measure>
    <time_frame>Week 96</time_frame>
    <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Viral Load Nadir, LOCF</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 56</measure>
    <time_frame>Week 56</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 2</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 24</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 32</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 40</measure>
    <time_frame>Baseline to Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 48</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 56</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 64</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 72</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 80</measure>
    <time_frame>Baseline to Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 88</measure>
    <time_frame>Baseline to Week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Change From Baseline in Viral Load to Week 96</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 2 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 4 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 8 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 16 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 24 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 32 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 40 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 48 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 56 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 64 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 72 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 80 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 80</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 88 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 88</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 96 in CD4+ Cell Count</measure>
    <time_frame>Baseline to Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to New CDC Class C Progression Event or Death.</measure>
    <time_frame>after 48 weeks of treatment</time_frame>
    <description>Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Viral Load Nadir, LOCF</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 32</measure>
    <time_frame>week 32</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 56</measure>
    <time_frame>Week 56</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 88</measure>
    <time_frame>week 88</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 400 Copies/ml) at Week 96</measure>
    <time_frame>week 96</time_frame>
    <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Viral Load Nadir, LOCF</measure>
    <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 32</measure>
    <time_frame>Week 32</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 40</measure>
    <time_frame>Week 40</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 56</measure>
    <time_frame>Week 56</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 64</measure>
    <time_frame>Week 64</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 72</measure>
    <time_frame>Week 72</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 80</measure>
    <time_frame>Week 80</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 88</measure>
    <time_frame>Week 88</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virologic Response (VL &lt; 50 Copies/ml) at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities</measure>
    <time_frame>240 Weeks</time_frame>
    <description>NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">630</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Tipranavir(TPV)/low dose ritonavir(r)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>Tipranavir(TPV)/low dose ritonavir(r)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir(r)</intervention_name>
    <arm_group_label>Tipranavir(TPV)/low dose ritonavir(r)</arm_group_label>
    <arm_group_label>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator Protease Inhibitor (CPI)</intervention_name>
    <arm_group_label>Comparator protease inhibitor(CPI)/low dose ritonavir(r)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients meeting the following criteria will be eligible for participation in th is study:

          1. Human Immunodeficiency virus 1 (HIV-1) infected males or females &gt;=18 years of age.

          2. Screening genotypic resistance report indicating both of the following: at least one
             primary protease Inhibitor (PI) mutation at the following sites:

        30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M, and no more than two protease mutations on
        codons 33, 82, 84, or 90.

        3. At least 3 consecutive months experience taking antiretrovirals (ARVs) from each of the
        classes of nucleoside reverse transcriptase inhibitors(NRTI(s)), non-nucleoside reverse
        transcriptase inhibitors(NNRTI(s)), and protease inhibitors (PIs) at some point in
        treatment history,with at least 2 protease inhibitor (PI)-based regimens, one of which must
        be the current regimen, and current protease inhibitor (PI)-based antiretroviral (ARV)
        medication regimen for at least 3 months prior to randomization.

        4. Human Immunodeficiency Virus 1 (HIV-1) viral load &gt;=1,000 copies/mL at screening.

        Exclusion criteria:

        Patients with any of the following criteria are excluded from participation in t he study:

          1. Antiretroviral (ARV) medication naïve.

          2. Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for
             at least 7 consecutive days within the last 3 months.

          3. alanine aminotransferase (ALT) &gt;=3.0x upper limit of normal (ULN) and aspartate
             aminotransferase(AST) &gt;=2.5x upper limit of normal (ULN) (&gt;=Division of AIDS(DAIDS)
             Grade 1) at either screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1182.12.62 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.108 El Rio SIA</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.9 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.23 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.12 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.76 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.59 David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.82 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.97 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.69 UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.89 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.99 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.25 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.5 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.53 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.98 University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.7 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.52 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.70</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.79 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.77 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.93 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.45 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.75 CARES Resource</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.85 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.17 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.90 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.63 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.78 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.94 Infectious Disease Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.67 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.123 Infectious Disease Clinics of Emory</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.88 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.72 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.47 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.8 Family Practice Medical Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.3 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.49 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.32 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.48 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.33 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.44 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.95 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.81 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.30 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.6 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.100 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.41 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.61 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.13 University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.54 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.56 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.120 Department of Medicine, HIV/AIDS Program</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.14 Dybedal Center for Clinical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.87 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11 Wellness Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.4 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.21 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.40 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.68 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.34 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.22 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.36 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.58 Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.96 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.83 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.43 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.42 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.46 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.24 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.35 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.65 Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.80 Infectious Disease Institute Clinical Trials Unit</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.114 Pinnacle Health</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.28 University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.50 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.86 The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.10 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.116 Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.2 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.55 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.31 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.73 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.26 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.91 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.122 VCU Health Systems</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.15 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.29 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1401 St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1405 AIDS Research Initiative / Ground Zero</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1407 Holdsworth House General Practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1408 407 Doctors Pty Ltd.</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1403 Albion Street Centre</name>
      <address>
        <city>Surry Hills</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1406 Gold Coast Sexual Health Clinic</name>
      <address>
        <city>Miami</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.1404 Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monteal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.11013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1182.12.60 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Santurce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2003</study_first_submitted>
  <study_first_submitted_qc>February 7, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2003</study_first_posted>
  <results_first_submitted>September 9, 2009</results_first_submitted>
  <results_first_submitted_qc>November 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2009</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In the study there were 630 patients entered as stated in the protocol section. There were 10 patients not treated and are not included within the Participant Flow Module or any other analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
        </group>
        <group group_id="P2">
          <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
          <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Set, all patients treated with at least one dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
        </group>
        <group group_id="B2">
          <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
          <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="620"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="7.9"/>
                    <measurement group_id="B2" value="44.5" spread="7.1"/>
                    <measurement group_id="B3" value="45.1" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response at Week 48</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>At week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.80"/>
                    <measurement group_id="O2" value="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Treatment Failure Through 48 Weeks of Treatment</title>
        <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure Through 48 Weeks of Treatment</title>
          <description>Time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="313"/>
                <count group_id="O2" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="0" upper_limit="395"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 24</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 24</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8"/>
                    <measurement group_id="O2" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 2</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 2</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 4</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 4</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 8</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 8</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.4"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 16</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 16</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 24</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 24</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 32</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 32</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 32</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 40</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 40</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 40</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.4"/>
                    <measurement group_id="O2" value="17.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 48</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 48</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 56</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 56</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5"/>
                    <measurement group_id="O2" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 64</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 64</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 72</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 72</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 72</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 80</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 80</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 80</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 88</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 88</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 88</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Response at Week 96</title>
        <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
        <time_frame>Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response at Week 96</title>
          <description>Treatment response (TR) is defined as two consecutive VL ≥ 1 log10 below baseline without discontinuation of study drug, change in anti-retroviral background, or rebound</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Weighted by the size of enfuvirtide and protease inhibitor strata</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure Through 96 Weeks of Treatment</title>
        <description>time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
        <time_frame>Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure Through 96 Weeks of Treatment</title>
          <description>time to treatment failure is defined as 0 for patients who never achieve TR otherwise time to treatment failure is the earliest time of death, discontinuation of the study drug or introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background, or the first of two consecutive visits with VL measurements &lt;1 log10 below baseline.</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="0" upper_limit="858"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</title>
        <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed Virologic Failure Through 48 Weeks of Treatment</title>
          <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113" lower_limit="0" upper_limit="395"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</title>
        <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
        <time_frame>Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed Virologic Failure Through 96 Weeks of Treatment</title>
          <description>Time to virologic failure is defined as the time from the start of treatment to the last measurement with a viral load reduction greater than 1.0 log before a confirmed drop of viral load reduction below 1.0 log.</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116" lower_limit="0" upper_limit="858"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Viral Load Nadir, LOCF</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Viral Load Nadir, LOCF</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.1"/>
                    <measurement group_id="O2" value="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 2</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 2</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 4</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 4</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3"/>
                    <measurement group_id="O2" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 8</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 8</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9"/>
                    <measurement group_id="O2" value="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 16</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 16</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 24</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 24</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.1"/>
                    <measurement group_id="O2" value="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 32</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 32</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 32</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 40</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 40</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 40</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 48</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 48</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 56</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 56</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 64</title>
        <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
        <time_frame>Week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (Viral Load &gt;= 1 Log Drop) at Week 64</title>
          <description>Percentage of participants with Viral Load (VL) &gt;= 1 log reduction from baseline</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 2</title>
        <time_frame>Baseline to Week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 2</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" lower_limit="-1.87" upper_limit="-0.41"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-1.52" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 4</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 4</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" lower_limit="-2.15" upper_limit="-0.45"/>
                    <measurement group_id="O2" value="-0.46" lower_limit="-1.71" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 8</title>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 8</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.43" upper_limit="-0.24"/>
                    <measurement group_id="O2" value="-0.43" lower_limit="-1.64" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 16</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 16</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-2.5" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.32" lower_limit="-1.26" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 24</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 24</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" lower_limit="-2.5" upper_limit="-0.11"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.1" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 32</title>
        <time_frame>Baseline to Week 32</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 32</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" lower_limit="-2.42" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-0.87" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 40</title>
        <time_frame>Baseline to Week 40</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 40</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" lower_limit="-2.43" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-0.8" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 48</title>
        <time_frame>Baseline to Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 48</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" lower_limit="-2.34" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-0.81" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 56</title>
        <time_frame>Baseline to Week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 56</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" lower_limit="-2.32" upper_limit="-0.04"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-0.77" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 64</title>
        <time_frame>Baseline to Week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 64</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.29" upper_limit="-0.02"/>
                    <measurement group_id="O2" value="-0.23" lower_limit="-0.82" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 72</title>
        <time_frame>Baseline to Week 72</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 72</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-2.29" upper_limit="-0.05"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.76" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 80</title>
        <time_frame>Baseline to Week 80</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 80</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-2.24" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.79" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 88</title>
        <time_frame>Baseline to Week 88</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 88</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-2.28" upper_limit="-0.06"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.82" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Change From Baseline in Viral Load to Week 96</title>
        <time_frame>Baseline to Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Median Change From Baseline in Viral Load to Week 96</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Log(Copies/mL)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.24" upper_limit="-0.01"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-0.76" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 2 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 2 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="48"/>
                    <measurement group_id="O2" value="19" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 4 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 4 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="69"/>
                    <measurement group_id="O2" value="22" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 8 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 8 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="72"/>
                    <measurement group_id="O2" value="25" spread="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 16 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 16 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="92"/>
                    <measurement group_id="O2" value="30" spread="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 24 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 24 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="86"/>
                    <measurement group_id="O2" value="24" spread="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 32 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 32</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 32 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="91"/>
                    <measurement group_id="O2" value="26" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 40 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 40</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 40 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="100"/>
                    <measurement group_id="O2" value="24" spread="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 48 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 48 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="95"/>
                    <measurement group_id="O2" value="28" spread="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 56 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 56 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="104"/>
                    <measurement group_id="O2" value="26" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 64 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 64 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="107"/>
                    <measurement group_id="O2" value="26" spread="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 72 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 72</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 72 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="113"/>
                    <measurement group_id="O2" value="24" spread="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 80 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 80</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 80 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" spread="122"/>
                    <measurement group_id="O2" value="26" spread="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 88 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 88</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 88 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="126"/>
                    <measurement group_id="O2" value="29" spread="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 96 in CD4+ Cell Count</title>
        <time_frame>Baseline to Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 96 in CD4+ Cell Count</title>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Cells/mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="133"/>
                    <measurement group_id="O2" value="28" spread="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to New CDC Class C Progression Event or Death.</title>
        <description>Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death</description>
        <time_frame>after 48 weeks of treatment</time_frame>
        <population>Safety Analysis Set (SAF), includes all patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to New CDC Class C Progression Event or Death.</title>
          <description>Time to new Centers for Disease Control and Prevention (CDC) class C progression event (i.e., new AIDS defining illness) or death</description>
          <population>Safety Analysis Set (SAF), includes all patients treated with at least one dose of study medication</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448" lower_limit="448" upper_limit="448"/>
                    <measurement group_id="O2" value="284" lower_limit="284" upper_limit="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9894</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Viral Load Nadir, LOCF</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Viral Load Nadir, LOCF</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 2</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 2</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 4</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 4</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 8</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 8</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 16</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 16</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 24</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 24</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 32</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>week 32</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 32</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 40</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 40</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 40</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 48</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 48</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 56</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 56</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6"/>
                    <measurement group_id="O2" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 64</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 64</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 72</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 72</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 72</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 80</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>Week 80</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 80</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 88</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>week 88</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 88</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 96</title>
        <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
        <time_frame>week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 400 Copies/ml) at Week 96</title>
          <description>Percentage of participants with Viral Load &lt; 400 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Viral Load Nadir, LOCF</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 2 through Week 96 (at any point during trial)</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Viral Load Nadir, LOCF</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 2</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 2</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 2</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 4</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 4</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 4</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 8</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 8</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 8</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 16</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 16</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 16</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 24</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 24</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 24</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 32</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 32</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 32</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 40</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 40</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 40</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 48</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 48</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 48</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 56</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 56</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 56</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 64</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 64</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 64</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 72</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 72</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 72</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 80</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 80</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 80</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 88</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 88</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 88</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 96</title>
        <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
        <time_frame>Week 96</time_frame>
        <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Response (VL &lt; 50 Copies/ml) at Week 96</title>
          <description>Percentage of participants with Viral Load &lt; 50 copies/mL</description>
          <population>FAS, Full Analysis Set includes all randomized patients treated with at least one dose of study medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities</title>
        <description>NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
        <time_frame>240 Weeks</time_frame>
        <population>Safety Analysis Set with On-Treatment data (SAF-OT), all patients treated with at least one dose of study drug and have on-treatment laboratory values</population>
        <group_list>
          <group group_id="O1">
            <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
            <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
          </group>
          <group group_id="O2">
            <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
            <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Division of Acquired Immunodeficiency Syndrome (DAIDS) Grade 3 or 4 Laboratory Abnormalities</title>
          <description>NIH Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Adult Adverse Experiences, December 2004.</description>
          <population>Safety Analysis Set with On-Treatment data (SAF-OT), all patients treated with at least one dose of study drug and have on-treatment laboratory values</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="304"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Transaminase (ALT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.5"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Transaminase (AST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT or AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 240 weeks</time_frame>
      <desc>Adverse events were monitored throughout the study and reported in the case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tipranavir(TPV)/Low Dose Ritonavir(r)</title>
          <description>TPV 500 mg / Ritonavir 200 mg, twice daily</description>
        </group>
        <group group_id="E2">
          <title>Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r)</title>
          <description>lopinavir, amprenavir [or fosamprenavir], saquinavir or indinavir combined with low-dose (100-200 mg) Ritonavir (RTV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Methaemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ventricle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fanconi syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sudden visual loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Stomatitis necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hepatosplenomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Immune reconstitution syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acquired immunodeficiency syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cavernous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus chorioretinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Disseminated cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>End stage AIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>HIV infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Herpes oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Injection site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Keratitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Meningitis cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mycobacterium avium complex infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Progressive multifocal leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis septic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Viral pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Foreign body trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood creatine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug level increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Volume blood decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neck mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Anal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hemicephalalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mental retardation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neurological symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Focal segmental glomerulosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Renal tubular acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Testicular mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Drug detoxification</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Intestinal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arterial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Exsanguination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="301" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="271" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

